Insomnia and Depression
A 50-year-old woman with a history of major depressive disorder, currently in remission, presents with a 3-month history of difficulty falling asleep and staying asleep. She reports lying awake for hours and feeling tired during the day. She denies suicidal ideation and has no other medical conditions. She takes sertraline 100 mg daily. She has tried over-the-counter sleep aids without relief. Her depression is well controlled, and she does not want to change her antidepressant. She asks about treatment options for her insomnia.
1. What is the most appropriate first-line treatment for this patient's insomnia?
Read the worked answer
The most appropriate first-line treatment for chronic insomnia is cognitive behavioral therapy for insomnia (CBT-I). CBT-I includes sleep restriction, stimulus control, cognitive restructuring, and relaxation techniques. It is effective and has durable benefits without the risks of pharmacotherapy. Although the patient has a history of depression, CBT-I can also improve mood. Pharmacotherapy (e.g., hypnotics) should be considered only if CBT-I is not effective or not available. Therefore, CBT-I is the first-line treatment.
2. If CBT-I is not available or fails, what pharmacologic options would you consider, and what are the precautions given her depression?
Read the worked answer
If CBT-I is not available or fails, pharmacologic options include non-benzodiazepine hypnotics (e.g., zolpidem, eszopiclone) or melatonin receptor agonists (e.g., ramelteon). However, precautions are necessary: benzodiazepines and Z-drugs can cause dependence and may worsen depression or increase fall risk; they should be used short-term and at the lowest effective dose. Ramelteon has no abuse potential and may be safer. Antidepressants with sedating properties (e.g., trazodone, doxepin) could be considered, but sertraline is already on board, and adding another serotonergic agent increases risk of serotonin syndrome. Low-dose doxepin (3-6 mg) is FDA-approved for sleep maintenance and has minimal anticholinergic effects. Therefore, non-benzodiazepine hypnotics or ramelteon are reasonable, with careful monitoring, and low-dose doxepin could be an option, but caution is needed due to her depression and current SSRI use.